Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H23NO3.CH4O3S |
| Molecular Weight | 409.496 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.[H][C@@]1(CNCCO1)[C@H](OC2=CC=CC=C2OCC)C3=CC=CC=C3
InChI
InChIKey=CGTZMJIMMUNLQD-STYNFMPRSA-N
InChI=1S/C19H23NO3.CH4O3S/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18;1-5(2,3)4/h3-11,18-20H,2,12-14H2,1H3;1H3,(H,2,3,4)/t18-,19-;/m1./s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Reboxetine is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has low affinity for other transporters and receptors. Reboxetine is used in acute treatment of depressive illness / major depression. Very common side effects are: difficulties to sleep (insomnia); dizziness; dry mouth; constipation; nausea (feeling sick); sweating. Based on studies conducted primarily outside the US, the FDA granted a preliminary letter of approval in 1999. However, more recent clinical studies conducted in the US and Canada, prompted by the FDA, resulted in a letter of non-approval.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Noradrenalin reuptake |
8.0 nM [IC50] | ||
Target ID: Serotonin reuptake |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | EDRONAX Approved UseReboxetine is indicated for the acute treatment of depressive illness/major depression and for maintaining the clinical improvement in patients initially responding to treatment. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. | 1995 Aug |
|
| Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition. | 1999 Oct |
|
| Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. | 2001 Dec |
|
| Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care. | 2002 Dec |
|
| Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors. | 2002 Nov-Dec |
|
| Acute akinetic crisis with marked cognitive impairment due to Valproate treatment. | 2003 Apr |
|
| The promises and pitfalls of reboxetine. | 2003 Winter |
|
| Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. | 2004 May 25 |
|
| Lercanidipine in hypertension. | 2005 |
|
| Nitrile glove permeation of benomyl. | 2006 Apr |
|
| Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. | 2006 Jul |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
| [Synthetic meshes for transvaginal surgical cure of genital prolapse: evaluation in 2005]. | 2006 Sep |
|
| Monotherapy with reboxetine in amphetamine withdrawal syndrome. | 2006 Sep 30 |
|
| [Advanced mesh implants for vaginal pelvic floor reconstruction: report of 100 prolift operations]. | 2007 Dec |
|
| Retrovesical haematoma after anterior Prolift procedure for cystocele correction. | 2007 Dec |
|
| Transvaginal repair of genital prolapse: preliminary results of a new tension-free vaginal mesh (Prolift technique)--a case series multicentric study. | 2007 Jul |
|
| Pelvic arterial embolization in the setting of acute hemorrhage as a result of the anterior Prolift procedure. | 2007 Jul |
|
| [The prosthetic kits in the prolapse surgery: is it a gadget?]. | 2007 May |
|
| [Prolift system in the correction of female genital prolapse]. | 2007 Sep |
|
| Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. | 2008 |
|
| Hormonal influences on cardiovascular norepinephrine transporter responses in healthy women. | 2008 Apr |
|
| Total Prolift System surgery for treatment posthysterectomy vaginal vault prolapse--do we treat both anatomy and function? | 2008 Dec |
|
| Short-term outcome after transvaginal mesh repair of pelvic organ prolapse. | 2008 Jun |
|
| What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? | 2008 May |
|
| Reutilization of the Prolift mark system for the simultaneous correction of prolapse and incontinence in patients with pelvic organ prolapse and stress urinary incontinence. | 2008 Nov |
|
| [Clinical study on concomitant surgery for stress urinary incontinence and pelvic organ prolapse]. | 2008 Oct 15 |
|
| Vaginal vault prolapse. | 2009 |
|
| A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine. | 2009 |
|
| [Transvaginal repair of genital prolapse with Prolift: evaluation of safety and learning curve]. | 2009 Feb |
|
| Short term impact on female sexual function of pelvic floor reconstruction with the Prolift procedure. | 2009 Nov |
|
| Laparoscopic sacrohysteropexy and myomectomy for uterine prolapse: a case report and review of the literature. | 2009 Nov 3 |
|
| Trocar-guided total tension-free vaginal mesh repair of post-hysterectomy vaginal vault prolapse. | 2009 Oct |
|
| [Correlation between stress urinary incontinence or urgency and anterior compartment defect before and after surgical treatment]. | 2010 Apr |
|
| Transvaginal mesh repair of anterior and posterior vaginal wall prolapse: a clinical and ultrasonographic study. | 2010 Apr |
|
| Permeation of chlorothalonil through nitrile gloves: collection solvent effects in the closed-loop permeation method. | 2010 Jul 15 |
|
| Mid-term results of pelvic organ prolapse repair using a transvaginal mesh: the experience in Sherbooke, Quebec. | 2010 Jun |
|
| Does trocar-guided tension-free vaginal mesh (Prolift) repair provoke prolapse of the unaffected compartments? | 2010 Mar |
|
| [Postoperative pain after transvaginal repair of pelvic organ prolapse with or without mesh]. | 2010 Nov |
|
| Pelvic magnetic resonance imaging for assessment of the efficacy of the Prolift system for pelvic organ prolapse. | 2010 Nov |
|
| Transurethral and suprapubic mesh resection after Prolift bladder perforation: a case report. | 2010 Oct |
|
| Now or later...Does timing of a midurethral sling in relation to transvaginal prolapse repair affect continence outcomes at 1 year? | 2010 Sep |
Sample Use Guides
8 mg a day (one 4 mg tablet twice a day). The maximum daily dose should not exceed 12 mg.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m9514
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL14370
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
98769-82-5
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
SUPERSEDED | |||
|
DTXSID8045690
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
SUB36041
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
KK-35
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
L94J81YNNY
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
C152163
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
98769-84-7
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
100000128681
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
127150
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
DBSALT000890
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | |||
|
60841
Created by
admin on Fri Dec 15 15:33:39 GMT 2023 , Edited by admin on Fri Dec 15 15:33:39 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SUBSTANCE RECORD
